🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 55

  1. (Z)-endoxifen

    ATOSSA THERAPEUTICS, INC.

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  2. -

    Talion

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  3. -

    Disc Medicine

    Intrahepatic cholangiocarcinoma (iCCA)

    phase 2 small molecule active

    1 trial

  4. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  5. -, -, -, MK-1200, -, -

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  6. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  7. -, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  8. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  10. -, PREDNISONE, PARACETAMOL , FLUDROCORTISONE , ABIRATERONE , -, HYDROCORTISONE, -, Ifinatamab Deruxtecan, -, -, HYDROCORTISONE, HYDROCORTISONE, Opevesostat, DOCETAXEL , ENZALUTAMIDE , PREDNISOLONE

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  11. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  12. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  13. 1-(3-(fluoro-18F)benzyl)guanidine ([18F]mFBG)

    Disc Medicine

    Pheochromocytoma – endocrine adrenal tumor

    phase 2 small molecule active

    1 trial

  14. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  15. 177Lu girentuximab

    Telix Innovations

    Advanced Cancer

    phase 2 small molecule active

    1 trial

  16. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  17. 177Lu-DOTA-TLX591

    Telix Innovations

    Prostate Cancer

    phase 2 mab completed

    1 trial

  18. 177Lu-J591

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  19. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  20. 177Lu-PSMA-617

    United Therapeutics Europe Ltd

    Metastatic Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  21. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  22. 2-deoxyglucose

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  23. 225Ac-J591

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule active

    2 trials

  24. 225Ac-LNC1011

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  25. 2X-121

    Allarity Therapeutics

    Advanced Ovarian Cancer

    phase 2 small molecule active

    1 trial

  26. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  27. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial

  28. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  29. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  30. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  31. 68Ga-Dotatoc

    Disc Medicine

    nasopharyngeal carcinoma

    phase 2 small molecule active

    1 trial

  32. 68Ga-FAP-CHX

    The First People's Hospital of Lianyungang

    Tumor

    phase 2 small molecule active

    1 trial

  33. 68Ga-FAPI-46

    The George Institute

    Non-metastatic Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  34. 68Ga-FAPI-46

    Istituto Gentili S.r.l.

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  35. 68Ga-FAPI-46

    The George Institute

    Triple-negative breast cancer (TNBC) patients at high risk of relapse

    phase 2 small molecule active

    1 trial

  36. 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

  37. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  38. 68Ga-NODAGA-SNA006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 2 small molecule active

    1 trial

  39. 68Ga-NY104 PET/CT

    Peking University Third Hospital

    Clear Cell Renal Cell Carcinoma

    phase 2 other active

    1 trial

  40. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  41. 6QC-ICG, Placebo for 6QC-ICG

    Disc Medicine

    Breast cancer

    phase 2 small molecule active

    1 trial

  42. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  43. 89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  44. 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

    Telix Innovations

    Cervical Cancer

    phase 2 other terminated

    1 trial

  45. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  46. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Cancer

    phase 2 small molecule active

    1 trial

  47. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  48. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Carcinoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.